The use of adalimumab in the treatment of acute intestinal graft-versus-host disease and enteropathy in children following allogeneic hematopoietic stem cell transplantation
Pediatric Hematology/Oncology and Immunopathology · 30.06.2026 · 25 (2) · 60-67
DOI: 10.24287/j.1104 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pediatric Hematology/Oncology and Immunopathology, online erschienen am 30.06.2026. Verfasst von Elena V. Skorobogatova und 3 weiteren Autor:innen. Die Arbeit nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Themen: Kinderkrankenpflege
Abstract (Originalsprache)
Introduction
Despite significant advances in the prevention and treatment of acute graft-versus-host disease (aGVHD) over the past decades, its severe forms remain one of the leading causes of mortality. Approaches to treating aGVHD and enteropathy are continually evolving. Presently, tumor necrosis factor inhibitors can be considered not only second- or third-line therapies but also first-line treatment. Aim: to explore the use of adalimumab in children with intestinal aGVHD and enteropathy. Materials and methods. This is the first Russian study on the use of adalimumab in children with intestinal aGVHD and enteropathy. From July 2025 to March 2026, the drug was administered to 5 children (4 boys and 1 girl): 3 of them with acute lymphoblastic leukemia, 1 with acute myeloid leukemia, and 1 with a congenital immune defect. The median age at the time of hematopoietic stem cell transplantation (HSCT) was 10 (4–16) years. Haploidentical HSCT was performed in 3 children, while the others underwent HSCT from HLA-matched unrelated donors. In 4 cases, native peripheral blood stem cells were used as the graft, and 1 patient received bone marrow-derived stem cells. For aGVHD prophylaxis/treatment, janus kinase inhibitors, cyclophosphamide, abatacept, rituximab, vedolizumab, tocilizumab, and etanercept were used. Adalimumab was indicated for enteropathy.
Results
Leukopoiesis recovery was achieved in all the patients within 15 (12–20) days, and complete donor chimerism has persisted since Day 30. In 3 out of 5 children, clinical response was observed after the first administration of adalimumab. One patient responded after the second administration: despite gastrointestinal contamination with Ps. aeruginosa and adenoviremia, escalation of immunosuppression did not affect resolution of the infection. In the patient with grade III–IV hepatic and intestinal aGVHD, a reduction to grade I was achieved after the 7th adalimumab administration. All the children are currently alive, and four of them do not require inpatient treatment.
Discussion
Our findings suggest that adalimumab has great therapeutic potential. By specifically targeting the key proinflammatory cytokine, tumor necrosis factor-alpha, it can quickly and effectively relieve severe manifestations of intestinal syndrome in patients at high risk of post-transplant progression of enteropathy of various etiologies.
Conclusion
Adalimumab may be considered for the treatment of aGVHD and enteropathy but its use requires careful monitoring of infectious risks when integrated into combination immunosuppressive therapy.
Zitieren
APA
Skorobogatova, E. V., Olkhova, L. V., Uvarov, A. K., & Tsimbalova, E. G. (2026). The use of adalimumab in the treatment of acute intestinal graft-versus-host disease and enteropathy in children following allogeneic hematopoietic stem cell transplantation. Pediatric Hematology/Oncology and Immunopathology, 25(2), 60-67. https://doi.org/10.24287/j.1104
Vancouver
Skorobogatova EV, Olkhova LV, Uvarov AK, Tsimbalova EG. The use of adalimumab in the treatment of acute intestinal graft-versus-host disease and enteropathy in children following allogeneic hematopoietic stem cell transplantation. Pediatric Hematology/Oncology and Immunopathology. 2026;25(2):60-67. doi:10.24287/j.1104
BibTeX
@article{Skorobogatova2026,
author = {Skorobogatova, Elena V. and Olkhova, L. V. and Uvarov, A. K. and Tsimbalova, E. G.},
title = {The use of adalimumab in the treatment of acute intestinal graft-versus-host disease and enteropathy in children following allogeneic hematopoietic stem cell transplantation},
journal = {Pediatric Hematology/Oncology and Immunopathology},
year = {2026},
volume = {25},
number = {2},
pages = {60--67},
doi = {10.24287/j.1104}
}
EUVIMED